Fichna et al. induced colitis in mice by the intracolonic administration of TNBS, and they observed that mice treated with the TRPV4 antagonist RN1734 showed a significant protection for the development of signs of colitis [11], suggesting that TRPV4 could constitute a promising pharmacological target for IBD treatment. This evidence concerns the gene TRPV4 and irritable bowel syndrome.